Clinical Research Directory

Inclusion Criteria: 1. "Negative control" population: subjects who have undergone genetic exploration and: * Having had a study of normal methylation of the 11p15 region (H19/IGF2: IG-DMR and KCNQ1OT1:TSS-DMR) by the reference technique. * And having had a sequencing study of one or more genes involved in a growth pathology (Sanger sequencing and/or NGS analysis) and having concluded in the presence of a pathogenic variant responsible for the pathology. OR Study population: \- subjects who had undergone a reference genetic investigation (ASMM-RTqPCR) and for whom the final diagnosis was: gain or loss of methylation at the H19/IGF2:IG-DMR locus (BWS,SRS), at the KCNQ1OT1:TSS-DMR locus (BWS) or at the DLK1/MEG3:IG-DMR locus (TS14). 2. Affiliation with a social security scheme or beneficiary (excluding AME). 3. Signature of the consent form by the subject's parents or guardians, or the subject if of age at the time of the study. Exclusion Criteria: * Inability of either the subject (if over 18) or the parents or holder of parental authority to receive informed information about the protocol. * Subject (if over 18) or parent or holder of parental authority deprived of their liberty by judicial or administrative decision